RT Journal Article
SR Electronic
T1 Acute graft-versus-host disease after allogeneic bone marrow transplantation
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 969
OP 974
VO 129
IS 9
A1 C. Perreault
A1 M. Gyger
A1 J. Boileau
A1 Y. Bonny
A1 S. Cousineau
A1 M. Lacombe
A1 R. Lavallee
A1 E. Tawil
A1 G. D'Angelo
YR 1983
UL http://www.cmaj.ca/content/129/9/969.abstract
AB In 25 patients receiving allogeneic bone marrow transplants methotrexate was used to prevent acute graft-versus-host disease (GVHD). Acute GVHD, grades 2 to 4, developed in only 5 (20%) of the patients. The incidence of acute GVHD in other series of recipients of bone marrow transplants has ranged from 5% to 76%. A review of the literature suggests that this variation cannot be completely accounted for by age, type of disease treated by transplantation or type of GVHD prophylaxis. However, transfusion of allogeneic lymphocytes that have not been completely inactivated by irradiation (e.g., in platelet and granulocyte preparations) and inadequate isolation-decontamination procedures may increase the probability of GVHD following bone marrow transplantation.